促红细胞生成素对肿瘤性贫血的临床应用研究  

Analysis on Hemopoietin's Clinical Application in Tumor Anemia

作　　者：乔姝[1] 杨丽[1] 白强[1] 

机构地区：[1]包头医学院第一附属医院,内蒙古包头014010

出　　处：《中国医学创新》2013年第30期3-4,共2页Medical Innovation of China

摘　　要：目的:探讨促红细胞生成素对肿瘤性贫血的临床治疗效果。方法:选取肺癌患者70例,随机分为实验组与对照组,每组35例,实验组患者在采用化疗治疗的基础上,加以1000单位/次,皮下注射促红细胞生成素,1周2次;对照组患者采用常规化疗。治疗8周后,观察两组患者治疗前后的血红蛋白(Hb)、红细胞比容(HCT)、网织红细胞百分数(RET%),并观察患者有无药物治疗反应。结果:治疗8周后,实验组的Hb平均值为(110.1±6.8)g/L,HCT平均值为(35.8±3.7)Vol%,RET的平均值为(1.76±0.07)%,均较治疗前明显升高(P<0.05);对照组患者的Hb平均值为(78.4±5.6)g/L,HCT平均值为(19.7±3.7)Vol%,RET的平均值为(0.91±0.06)%,较治疗前无明显变化(P>0.05)。此外,实验组经治疗时未发现有明显的并发症。结论:促红细胞生成素治疗肿瘤性贫血临床效果显著,无明显毒副作用,临床上值得应用。Objective： To discuss hemopoietin＇s clinical treatment effects on tumor anemia. Method： To choose 70 lung cancer patients, and divide them into experimental group and control group, and each group had 35 eases. To add 1000 units/time of hemopoietin subcutaneous injection to experimental group＇s patients on the basis of chemotherapy, two times each week. While to adopt conventional chemotherapy to control group＇s patients. After 8 weeks of treatment, to observe the two groups＇ hemoglobin, hematocrit value, and retieulocyte percentage, and whether they had had drug treatment responses. Result： After 8 weeks of treatment, experimental group＇s Hb average value was （ 110.1 ± 6.8 ） g/L, HCT average value was （ 35.8 ± 3.7 ） Vol%, RET＇s was （ 1.76 ± 0.07 ） %, these three values increased significantly when compared with before treatment （ P〈0.05 ） . Control group＇s Hb average value was （ 78.4 ± 5.6 ） g/L, HCT average value was （ 19.7 ± 3.7 ） Vol%, RET＇s was （ 0.91 ± 0.06 ） %, these three values did not obviously change compared with before treatment （ P〉0.05 ） . Moreover, experimental group＇s patients did not occur evident complications. Conclusion： Hemopoietin has significant clinical effect on tumor anemia, it does not have obvious toxic and side effect, and is worthy of clinical application.

关 键 词：促红细胞生成素 肿瘤 贫血 化疗 

分 类 号：R692.5[医药卫生—泌尿科学]